Status:
COMPLETED
High Water Intake to Slow Progression of Polycystic Kidney Disease
Lead Sponsor:
NYU Langone Health
Conditions:
Kidney, Polycystic, Autosomal Dominant
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Polycystic kidney disease (PKD) is a genetic disease that occurs in 1 in 500 individuals and leads to kidney failure in half of all affected. Currently, no treatments exist for PKD. PKD-affected kidne...
Eligibility Criteria
Inclusion
- Clinical diagnosis of Autosomal Dominant Polycystic Kidney Disease by history, ultrasound, CT or MRI
- Healthy subjects without a diagnosis of Polycystic Kidney Disease by history, ultrasound, CT or MRI
- Ages between 18 and 65
- Healthy subjects (without Polycystic Kidney Disease) must have an estimated glomerular filtration rate (eGFR by the MDRD equation) \> 60 ml/min/1.73 m2 with no history of kidney disease
Exclusion
- Women who are pregnant or nursing
- Active dependency on drugs or alcohol
- Diagnosis of syndrome of inappropriate antidiuresis
- Currently taking a vasopressin agonist or antagonist
- Blood sodium level less than \< 135 mEq/L
- For healthy participants, estimated glomerular filtration rate (level of kidney function) less than \< 60 ml/min/1.73 m2
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT00784030
Start Date
November 1 2008
End Date
May 1 2009
Last Update
April 6 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York University Langone Medical Center
New York, New York, United States, 10016